DexaJect is indicated as an anti-inflammatory agent use for the treatment of primary bovine ketosis and equine. As supportive therapy, Dexaject used in the management of various rheumatic, allergic, dermatologic, and other diseases known to be responsive to anti-inflammatory corticosteroids.
This page contains information on DexaJect for veterinary use.
The information provided typically includes the following:
Warnings and cautions for DexaJect
Direction and dosage information for DexaJect
This treatment applies to the following species:
Company: Henry Schein® Animal Health
2 mg per mL
ANADA #200-312, Approved by FDA
FOR ANIMAL USE ONLY
KEEP OUT OF REACH OF CHILDREN
Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Treatment may be changed over to DEXAJECT™ from any other glucocorticoid with proper reduction or adjustment of dosage.
Bovine: DEXAJECT 5 – 20 mg intravenously or intramuscularly.
Equine: DEXAJECT 2.5 – 5 mg intravenously or intramuscularly. DexaJect DexaJect DexaJect DexaJect DexaJect